

TOYAM77.001AUS



COPY OF PAPER  
ORIGINALLY FILED

#6

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Imai, et al.	)	Group Art Unit Unknown
			)	
Appl. No.	:	09/963,316	)	
			)	
Filed	:	September 25, 2001	)	
			)	
For	:	USES OF ANTI-CX3CR1 ANTIBODY, ANTI- FRACTALKINE-ANTIBODY AND FRACTALKINE	)	
			)	
Examiner	:	Unknown	)	

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Prior to examination on the merits of the above-captioned application, please amend the above-identified application as follows:

IN THE SPECIFICATION:

Please amend the paragraph beginning at line 12 of page 8 as follows:

--Fig. 6 shows correlations between expressions of chemokine receptors other than CX3CR1 and expression of CX3CR1.--

REMARKS

The phrase "chemotaxis of killer lymphocytes" has been amended to --expression of CX3CR1--. That was a clerical error, and support for the amendment can be found in Figure 6. Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE." No new matter has been added. Applicant respectfully requests entry of the amendments.

Adjustment date: 05/02/2002 SSAL EEU  
03/21/2002 BARAHAI 00000029 09963316  
01 FC:117 -20.00 CR

Repln. Ref: 05/02/2002 SSAL EEU 0007102100  
000111410 Name/Number:09963316  
FC: 704 8920.00 CR

03/21/2002 BARAHAI 00000029 09963316

01 FC:117

-20.00 CR